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Abstract
Background: In recent years, capabilities for genotyping large sets of single nucleotide polymorphisms (SNPs) has increased
considerably with the abilityto genotypeover 1 millionSNP markersacrossthe genome.This advancementintechnologyhas
led to an increase in the number of genome-wide association studies (GWAS) for various complex traits. These GWAS have
resulted in the implication of over 1500 SNPs associated with disease traits. However, the SNPs identified from these GWAS
are not necessarily the functional variants. Therefore, the next phase in GWAS will involve the refining of these putative loci.
Methodology: A next step for GWAS would be to catalog all variants, especially rarer variants, within the detected loci,
followed by the association analysis of the detected variants with the disease trait. However, sequencing a locus in a large
number of subjects is still relatively expensive. A more cost effective approach would be to sequence a portion of the
individuals, followed by the application of genotype imputation methods for imputing markers in the remaining individuals.
A potentially attractive alternative option would be to impute based on the 1000 Genomes Project; however, this has the
drawbacks of using a reference population that does not necessarily match the disease status and LD pattern of the study
population. We explored a variety of approaches for carrying out the imputation using a reference panel consisting of
sequence data for a fraction of the study participants using data from both a candidate gene sequencing study and the
1000 Genomes Project.
Conclusions: Imputation of genetic variation based on a proportion of sequenced samples is feasible. Our results indicate
the following sequencing study design guidelines which take advantage of the recent advances in genotype imputation
methodology: Select the largest and most diverse reference panel for sequencing and genotype as many ‘‘anchor’’ markers
as possible.
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Introduction
In the last five years, the capabilities and technology for
genotyping large sets of single nucleotide polymorphisms (SNPs)
has increased significantly. Current genome-wide SNP arrays have
the capability to genotype over one million SNP markers across
the genome. This advancement in technology has led to an
increased number of completed and on-going genome-wide
association studies (GWAS) for various complex disease and
drug-related phenotypes. These GWAS have resulted in more
than 350 publications and over 1500 SNPs implicated for
association with multiple (.80) disease phenotypes or traits [1].
However, the SNPs identified are not necessarily the functional
variant and many GWAS studies are moving into the next phase
of disease mapping involving the validation, augmentation and
refining of these putative regions or loci [2]. The task of
determining the ‘‘causative’’ variant(s) is difficult since 43% of
associated SNPs are located in intergenic regions, and 45% are
located within intronic regions of known genes [1].
Indirect association, as a result of linkage disequilibrium (LD), is
a key factor in the success of genetic association studies. As a result
of LD, a disease-susceptibility SNP need not be genotyped, as long
as it is ‘‘tagged’’ by a SNP or set of SNPs that are genotyped (i.e.,
SNPs in LD with the disease-susceptibility SNP are genotyped).
Recently this concept has been further exploited by the
introduction of methods to impute genotypes at untyped markers,
based on genotypes at typed markers and information about LD
within the region [3,4,5,6,7,8,9,10,11,12]. These methods are
particularly useful in the context of failed genotyping and
combining data across multiple platforms and recently have been
extended to untyped markers using a reference data set [8,10,11].
One approach for following up replicated findings from a
GWAS would be to determine all genetic variation within the
locus, especially rarer variants not currently included on GWAS
SNP arrays, as they may play an important role in the etiology of
the disease [13]. This could be accomplished using the 1000
Genomes Project. However, one limitation of the use of 1000
Genomes Project for imputation of markers in a locus of interest is
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represented in this relatively ‘‘healthy’’ cohort. An alternative
approach would be to catalog all variants by sequencing the locus
in the study subjects [14], followed by association analysis of each
variant in the locus. However, sequencing is still relatively
expensive and it may be cost prohibitive to sequence a region
on a large set of individuals. A more cost effective approach would
be to sequence a portion of the individuals, possibly selected based
on the distribution of the phenotype and/or haplotypes, and then
employ genotype imputation methods [15,16,17,18] for imputing
the sequenced markers in the remaining individuals. This
approach could also be augmented with the additional inclusion
of data from the 1000 Genomes Project.
In this manuscript we explore the use of the recently developed
genotype imputation method implemented in MACH [16] for
sequencing studies with the goal of localizing possible functional
variants through statistical analysis. In doing so, we explore a
variety of approaches for carrying out the imputation of untyped
markers using a reference panel consisting of sequencing data for a
fraction of the study participants. The various approaches are
implemented using data from a candidate gene sequencing study
conducted at the Mayo Clinic and data from the 1000 Genomes
Project (http://www.1000genomes.org) [19].
Materials and Methods
Mayo Sequencing Study: GENE1
To explore various approaches for imputation of untyped
markers using a reference panel determined from sequencing data,
we utilized a recently completed sequencing study for a gene
which we will denote as GENE1 (unpublished data). Little is known
in regard to common genetic variations within GENE1, and even
Table 1. Summary of sequence data for GENE1 for variants with MAF.1% or in HapMap.
African American White non-Hispanic American Han Chinese American
Marker Position ObsHET MAF ObsHET MAF ObsHET MAF
1* 1270 0.385 0.203 0.415 0.303 0.474 0.416
5* 1541 0.365 0.182 0.427 0.307 0.479 0.417
6 1753 0 0 0.021 0.01 0 0
8 1811 0.021 0.01 0.031 0.026 0 0
9* 1812 0.062 0.031 0.104 0.062 0.26 0.193
10 1962 0 0 0.021 0.01 0 0
11* 1968 0 0 0 0 0.135 0.068
16 2829 0.021 0.01 0 0 0 0
17 3092 0 0 0 0 0.021 0.01
18 3145 0 0 0 0 0.021 0.01
19 3150 0.083 0.052 0 0 0 0
21 3456 0.521 0.396 0.417 0.312 0.469 0.411
22 3525 0 0 0 0 0.052 0.036
24 4399 0.115 0.057 0 0 0.146 0.083
25* 4467 0.052 0.026 0 0 0.146 0.083
27 4893 0.042 0.021 0 0 0 0
28* 5016 0.01 0.005 0 0 0 0
29* 5031 0 0 0.052 0.026 0 0
33* 5523 0.053 0.026 0.083 0.042 0.26 0.193
37 5974 0.021 0.011 0.042 0.021 0 0
39* 6166 0.385 0.203 0.469 0.432 0.365 0.224
40 6237 0.021 0.01 0 0 0 0
41 6265 0 0 0 0 0.062 0.031
42* 6311 0.01 0.005 0 0 0 0
44 6862 0 0 0.052 0.026 0 0
45 7036 0.031 0.016 0 0 0 0
48 7262 0 0 0 0 0.073 0.057
57* 7975 0.031 0.016 0 0 0 0
58 8057 0.021 0.01 0.094 0.047 0.011 0.005
59 8187 0.021 0.01 0 0 0 0
60 8230 0.021 0.01 0 0 0 0
*SNP Marker in HapMap; used as typed genotypes in all samples (i.e., markers on a GWAS SNP array).
MAF=minor allele frequency based on imputed ‘‘dosage’’ or expected genotype, position=physical base-pair location of the SNP based on build 36,
ObsHET=observed heterozygote rate.
doi:10.1371/journal.pone.0011018.t001
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with protein function or clinical phenotypes. In an attempt to
address these issues, we have sequenced GENE1 in 288 samples
from the Coriell Institute’s publically available ‘‘Human Varia-
tion Panel’’ (http://ccr.coriell.org/Sections/Collections/NIGMS/
Populations.aspx?PgId = 177&coll = GM), consisting of 96 Afri-
can American (AA), 96 Caucasian American (CA), and 96 Han
Chinese American (HCA). DNA was extracted by the Coriell
Institute from EBV transformed lymphoblastoid cell lines.
As a consequence of GENE1 being a relatively short gene (5 kb),
the entire gene was sequenced using Sanger sequencing technol-
ogy. PCR primers were designed to span the entire gene plus 1 kb
beyond the 59 and 39 UTR. PCR products were bi-directionally
sequenced on an Applied Biosystems 3730 DNA Analyzer and
analyzed with SoftGenetic’s Mutation Surveyor software. Sixty
variants were cataloged across the three racial groups; eleven of
these variants were previously-known SNPs that have entries in
dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP/). Table 1
presents a summary of the 31 polymorphisms that are either
contained in HapMap (www.hapmap.org) or have a minor allele
frequency (MAF).1%.
1000 Genomes Project: COMT
The initial goal of the 1000 Genomes Project was to sequence
the entire genome in approximately 1200 individuals as a means of
documenting all human genetic variation. Recently, the number of
samples to be sequenced has increased to over 2000 samples [20].
As of September 20, 2009 (release 2009_04), there were 172
HapMap samples sequenced from three racial groups (57 U.S.
residents with northern and western European ancestry (CEU), 56
Yoruba people of Ibadan, Nigeria (YRI) and 59 individuals from
the Tokyo, Japan and Beijing, China (JPNCHB)) available for
download and analysis from the 1000 Genomes Project. The data
was part of a Pilot Project, in which samples were sequenced at, on
average, 2x–4x coverage using ABI’s SOLiD, Roche’s 454 and
Illumina’s Solexa sequencing technologies. This pilot study was
completed by the 1000 Genomes Consortium to evaluate the use
of LD information and sequence data from multiple samples to aid
in the genotype calling from low coverage, whole genome
sequencing (http://www.genome.gov/26524516). Once down-
loaded, we focused on the region of the genome where the gene
COMT is located based on the March 2006 build of the human
genome as shown on the UCSC genome browser at http://
genome.ucsc.edu/ (chromosome 22, 18243040–18336530). Four-
hundred and six SNP markers were determined to be in the CEU
population, 517 SNP markers in the YRI population and 290 SNP
markers in the JPTCHB population.
Genotype Imputation using Sequencing Data
To explore various approaches for imputing untyped markers to
augment sequence data, using a reference panel determined from
sequencing a portion of the study participants, we will utilize
sequence data available for GENE1 and COMT. To assess the
various approaches, we have created the following hypothetical
experiment. A SNP marker within a gene (e.g., GENE1 or COMT)
has been determined to be associated with a disease phenotype
based on a large GWAS, in which all subjects have been
genotyped for a set of SNPs on a large SNP array (e.g., Affymetrix
Genome-Wide Human SNP Array 6.0 or Illumina human1M-duo
array). The GWAS consists of subjects from three different racial
groups. To follow-up the association findings, denser genotyping
of the gene using sequencing technologies (Sanger or Next-
Generation) was completed in a proportion of the individuals from
each racial group. Based on the sequence data for the subset of the
study participants, we wish to impute untyped markers for the
remaining subjects using current genotype imputation methods.
Based on previous reports regarding comparison of genotype
imputation methods [21,22,23], we have elected to use MACH for
the imputation [16].
In assessing the use of sequence data for genotype imputation,
the experiment varied: the proportion of samples sequenced (or
the size of the reference data), the number of markers genotyped
for all subjects (‘‘anchor’’ SNPs) and how these markers were
selected, imputation based on the sequenced participants (‘‘refer-
ence panel’’) unphased genotypes or most-likely phased haplotypes
and imputation based on race specific reference haplotypes or all
reference haplotypes (regardless of race). The various simulation
scenarios investigated using GENE1 from the Mayo Study and
COMT from the 1000 Genomes Project are outlined in the
following sections.
To assess the accuracy of the various simulation scenarios, we a
priori determined the samples to be considered the reference panel,
Table 2. Imputation Scenario Design Summary.
Factors Varied for Imputation Scenario
12 3 4
Use of Phased Reference Haplotypes for Imputation
Most likely phase reference haplotypes XX X
Unphased genotypes X
Reference Haplotypes
Race specific reference haplotypes XX
All reference haplotypes, regardless of race X
Number of Markers Genotyped on All Subjects
GENE1 Three X
Five X
Seven X
Ten XX X
COMT Tag SNPs XX X
SNPs on GWAS array X
doi:10.1371/journal.pone.0011018.t002
Table 3. Concordance values between the ‘‘true’’ genotype
and most likely imputed genotype for GENE1 for Scenarios 1,
2 and 3.
Proportion Sequenced
Scenario Race 0.1 0.2 0.3 0.4 0.5
1 AA 0.962 0.965 0.973 0.962 0.974
CA 0.988 0.991 0.968 0.989 0.964
HCA 0.963 0.973 0.969 0.964 0.97
2 AA 0.975 0.971 0.975 0.972 0.971
CA 0.985 0.978 0.978 0.976 0.977
HCA 0.98 0.975 0.976 0.975 0.978
3 AA 0.969 0.971 0.973 0.975 0.97
CA 0.977 0.972 0.972 0.971 0.972
HCA 0.968 0.972 0.972 0.972 0.972
doi:10.1371/journal.pone.0011018.t003
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considered the ‘‘observed’’sample, non-anchor SNPswere masked,
but retained and considered to be the ‘‘true’’ genotypes. These
‘‘true’’ genotypes could then be compared to the imputed markers
arrived at using MACH’s most likely genotype call, with anchor
SNPs in common between the reference population and ‘‘ob-
served’’ sample. In addition to computing the concordance rates
based on most likely genotypecall, we also used the –mask option in
MACH to compute quality measures for the imputed markers and
estimated MAF based on the expected genotype (i.e., dosage).
Imputation Scenarios for GENE1
Table 2 displays the various genotype imputation scenarios
investigated for use with sequence data. The first simulation
scenario (Scenario 1) was one in which the reference haplotypes
for the sequenced samples was determined using the most likely
haplotypes produced by fastPHASE [24]. The eleven prior known
SNP markers were treated as the ‘‘anchor’’ markers genotyped on
all subjects with the remaining markers sequenced in a portion of
the subjects. The haplotype estimation and the genotype
imputation were both completed by race.
In Scenario 2, imputation was completed by race (as for
Scenario 1), but imputation was based on all reference haplotypes
for all three races. To assess the variation in haplotype assignment
and impact on imputation accuracy, imputation Scenario 3 was
completed, by race, with only unphased genotypes for the
sequenced samples (i.e., no phased reference haplotypes used). It
should be noted that not all genotype imputation methods allow
for the use of only unphased genotypes and may require reference
haplotypes. Lastly, Scenario 4 assessed the impact of the number
of ‘‘anchor’’ markers genotyped for all subjects, with either 3
markers (Scenario 4.3), 5 markers (Scenario 4.5), or 7 markers
(Scenario 4.7) used in the imputation with the same design as
Scenario 1.
Imputation Scenarios for COMT
For the COMT study, based on data from the 1000 Genomes
Project, the ‘‘anchor’’ markers were selected for two situations: a
candidate gene study (Scenarios 1, 2 and 3) and a genome-wide
association study (Scenario 4) (Table 2). Scenarios 1, 2 and 3 were
similar to the corresponding scenarios for GENE1. For scenario 4
the COMT and GENE1 scenarios differed in implementation.
Scenario 4 for GENE1 was used to assess the impact of varying the
number of anchor markers (either 3, 5 or 7), while for COMT this
scenario assessed the impact of how the ‘‘anchor’’ markers were
selected: one based on candidate gene study in which SNPs were
Figure 1. Comparison of mean SNP imputation quality score between the various imputation scenarios for GENE1. The proportion of
the sample used as the reference panel is displayed on the X-axis and the mean SNP imputation quality score is displayed on the Y-axis.
doi:10.1371/journal.pone.0011018.g001
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SNPs on a GWAS SNP array. SNPs were defined to be on the
GWAS panel if they were contained in HapMap, as many large
GWAS SNP arrays are designed based on HapMap SNPs.
To mimic the candidate gene scenario, we consider the
common situation where the anchor markers, genotyped on all
subjects, would be LD based tag SNPs. Therefore, to determine
anchor markers for COMT, tagging was completed by race using
Haploview v4.1 [25] with a minimum inclusion minor allele
frequency (MAF) of 0.05 and a r
2 of 0.8. This resulted in 125, 187
and 117 tagSNPs selected for CEU, YRI, and JPNCHB
populations, respectively. These markers, for each race, were
then taken to be the ‘‘anchor’’ markers genotyped on all samples in
the candidate gene study. To mimic the case in which the
‘‘anchor’’ markers were on a genome-wide SNP array (Scenario
4), SNPs were chosen as any SNPs present in HapMap, resulting
in 25 for the CEU population, 50 SNPs in the JPTCHB
population and 32 SNPs in the YRI population [26].
Results
Genotype Imputation for GENE1
Sequencing of GENE1, using Sanger Sequencing technology,
detected five novel variants with MAF greater than 5% and 20
novel variants with MAF greater than 1% not previously reported
(Table 1). None of the SNP genotypes deviated from Hardy-
Weinberg equilibrium, where HWE was tested by race using
Haploview [25]. By using our study population consisting of
Caucasian Americans (CA), African Americans (AA) and Han-
Chinese Americans (HCA), we are able to ensure the compara-
bility of LD structure used in the imputation. This may not be true
if the 1000 Genomes Project data were to be used, as the
Figure 2. Comparison of minimum SNP imputation quality score between the various imputation scenarios for GENE1. The proportion
of the sample used as the reference panel is displayed on the X-axis and minimum SNP imputation quality score is displayed on the Y-axis.
doi:10.1371/journal.pone.0011018.g002
Table 4. Concordance values between the ‘‘true’’ genotype
and most likely imputed genotype for GENE1 for various
number of ‘‘anchor’’ markers.
Number of Anchor Markers
Race 3 5 7 11
AA 0.966 0.972 0.973 0.974
CA 0.952 0.960 0.962 0.964
HCA 0.958 0.962 0.972 0.970
Table presents results for scenario with 50% of the samples sequenced.
doi:10.1371/journal.pone.0011018.t004
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scenarios for genotype imputation using sequence data for
polymorphic markers in gene GENE1 was completed using
MACH 1.0 (http://www.sph.umich.edu/csg/abecasis/mach/in-
dex.html) using the commands: mach1 -d markers.dat -p
pedigree.ped -h hap.haplos -s all.snp --rounds
150 --greedy --mask 0.02 --geno --dosage --
quality -o machOut for scenarios using reference haplotypes
and mach1 -d markers.dat -p pedigree.ped --rounds
150 --greedy --mask 0.02 --geno --dosage --
quality -o machOut for the scenarios in which only unphased
genotypes were used in the imputation (Scenario 3). Percent of
concordant genotype calls was computed by comparing the
imputed genotypes to the ‘‘true’’ observed genotypes.
Table 3 displays the concordance rates for Scenarios 1, 2, and
3, while Figures 1 and 2 display the mean and minimum SNP
quality score, as provided by MACH (based on expected imputed
genotype), for the three races and three scenarios. In the AA and
HCA groups, using only race specific reference haplotypes
(Scenario 1) produced the lowest mean quality scores and
concordance for imputation. This observation agrees with other
publications, which state that a more diverse set of reference
haplotypes increases the accuracy in imputation [27]. For
imputation of CA, the results were similar between the three
methods for imputation, with Scenarios 1 and 2 producing the best
concordance and Scenarios 1 and 3 producing the highest mean
and minimum quality score. In terms of the impact of the number
of ‘‘anchor’’ markers on imputation, the greater the number of
markers, the higher the quality and concordance in imputation.
Table 4 shows the concordance as a function of number of
‘‘anchor’’ markers when 50% of the samples where sequenced; the
same trend was observed when a smaller proportion of samples
were sequenced and used as the reference (data not shown).
Lastly, in general, as the proportion (or number) of samples
sequenced increased (i.e., larger set of reference haplotypes), the
quality of the imputation increased. Thus, not only does number
of markers genotyped on all subject impact the accuracy of
imputation, so does the size of the reference sample. In addition to
variation in results due to the number of markers genotyped on all
subjects and size of the reference set, two different reference sets of
the same size (i.e., different samples selected for sequencing)
resulted in slightly different imputation accuracy (data not shown).
Genotype Imputation with 1000 Genomes Project
The various scenarios for genotype imputation using the 1000
Genomes Project sequence data for polymorphic markers in
Figure 3. Comparison of concordance rates between the various imputation scenarios for COMT. The proportion of the sample used as
the reference panel is displayed on the X-axis and the percent concordant between the ‘‘true’’ genotype and the imputed most likely genotype is
displayed on the Y-axis.
doi:10.1371/journal.pone.0011018.g003
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using the commands: mach1 -d markers.dat -p pedi-
gree.ped -h hap.haplos -s all.snp --rounds 150 --
greedy --mask 0.02 --geno --quality -o machOut for
all scenarios.
As completed for GENE1, we looked at the SNP concordance
rates and SNP quality score for COMT for the various imputation
scenarios (Figures 3 and 4). Figures 3 and 4 display the
relationship between the concordance and minimum quality score
for the four scenarios in relation to the proportion of the
population sequenced. In terms of highest minimum quality score,
imputation based on reference haplotypes for all races (Scenario 2)
was the ‘‘best’’; however in terms of concordance between the
observed and imputed most likely genotype, imputation based on
race specific reference haplotypes was ‘‘best’’ (Scenario 1). The
range (minimum – maximum) in mean concordance rates for
Scenario 1 was 0.82–0.87 for CEU, 0.86–0.88 for JPTCHB and
0.87–0.92 for YRI.
The figures and table show that anchor SNPs based on a tag
SNP approach dramatically outperformed the approach where
anchor SNPs were based on a large SNP array (Scenario 4), in
terms of both concordance rates and minimum SNP quality
scores. In terms of highest minimum quality score, imputation
based on reference haplotypes for all races (Scenario 2) was the
‘‘best’’; however in terms of concordance between the observed
and imputed most likely genotype, imputation based on race
specific reference haplotypes was ‘‘best’’ (Scenario 1). The figures
also show a slight increase in imputation performance as the size of
the reference panel increased.
Lastly, with one goal of sequencing to be to detect rare variants,
we compared, for the three races, the relationship between the
estimated MAF, based on the imputed dosage, after imputation
and the quality of imputation (Figure 5). We observed the mean
quality score decreased as the MAF increased and that as the
proportion of samples sequenced increased, the average imputa-
tion accuracy improved for common variants.
Discussion
In this manuscript present the use of the recently developed
genotype imputation method for sequencing studies, where the
reference panel consisting of sequencing data for a fraction of the
study participants. By sequencing only a portion of the samples for
the follow-up of signals detected from a GWAS, followed by
imputation in the remaining samples, one can significantly reduce
the cost to localize the punitive variant involved in the etiology of
complex disease and pharmacogenomic phenotypes. In addition,
by utilizing sequence data on a portion of individuals in the study,
Figure 4. Comparison of minimum SNP imputation quality score between the various imputation scenarios for COMT. The proportion
of the sample used as the reference panel is displayed on the X-axis and the minimum SNP imputation quality score is displayed on the Y-axis.
doi:10.1371/journal.pone.0011018.g004
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of linkage disequilibrium, without relying on the assumption that
the HapMap populations represent our study population (as
HapMap based haplotypes are the current standard reference data
used for genotype imputation).
Sequencing a portion of our study population also allows us to
determine and assess association of rare variants not present in the
HapMap database. Upon completion of the 1000 Genomes
project (http://www.1000genomes.org), incorporation of this
information can also be utilized to determine variants not already
identified in public databases. However, one limitation of the use
of 1000 Genomes project for imputation for all subjects is the
possibly that this ‘‘healthy’’ cohort does not adequately represent
the genetic diversity observed in the affected individuals (i.e.,
individuals with the disease). Thus, there will still be a need to
sequence individuals, in particular, those individuals with the
disease or phenotype of interest.
Our results, based on a Sanger sequencing study of a candidate
gene and preliminary data from the 1000 Genomes Project for
COMT, show that imputation of untyped markers based on
sequencing a portion of the study participants is a reasonable, cost-
saving approach for disease mapping and refinement of putative
regions detected with GWAS. However, there was not a clear
scenario that was the ‘‘best’’ for genotype imputation across the
two genes and three races. At the completion of the 1000
Genomes Project, future research will be needed to determine
optimal approaches to incorporate this valuable information to
inform future genetic association studies. In addition, further
research is needed to develop cost effective sequencing study
designs and analysis methods that incorporate the uncertainty in
the reference haplotypes and imputation into the association
analysis. Based on results from this study, we recommend a few
guidelines in designing sequencing studies to take advantage of the
recent advances in genotype imputation methodology:
(1) Select the largest and most diverse reference panel for
sequencing, with respect to both haplotypes and phenotype.
One can also use sequencing data from the 1000 Genomes
data in addition to the sequencing of a portion of the study
participants (i.e., reference panel consists of data from
sequencing a portion of individuals with the disease/
phenotype of interest and data from the 1000 Genomes
Project)
(2) Given that sequencing produces unphased genotypes, if
possible, imputation should be carried out on the unphased
genotypes in the reference panel as opposed to the most likely
Figure 5. Comparison of mean SNP imputation quality score versus MAF for COMT imputation scenario 1. The MAF (group 1:
0#MAF#0.05, group 2: 0.05,MAF#0.10, group 3: 0.10,MAF#0.20, group 4: 0.20,MAF#0.30, group 5: 0.30,MAF#0.40, group 6: 0.40,MAF#0.50)
is displayed on the X-axis and the mean SNP imputation quality score is displayed on the Y-axis.
doi:10.1371/journal.pone.0011018.g005
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assignment.
(3) Genotype as many ‘‘anchor’’ markers as possible, in that, the
number of markers genotyped on all subjects impacts
accuracy. Therefore, additional genotyping of a few common
SNP markers not already genotyped on all subjects using a
cost effective platform, like Taqman, may be needed if the
GWAS SNP array does not provide adequate coverage in the
locus to be sequenced.
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